	US 11,866,730 B2
	Cytopheresis cartridges and use thereof
H. David Humes, Ann Arbor, MI (US); Deborah A. Buffington, Ann Arbor, MI (US); and Christopher J. Pino, Saline, MI (US)
Assigned to SeaStar Medical, Inc., Denver, CO (US)
Filed by SeaStar Medical, Inc., Denver, CO (US)
Filed on Sep. 13, 2021, as Appl. No. 17/473,176.
Application 17/473,176 is a division of application No. 15/664,884, filed on Jul. 31, 2017, granted, now 11,118,162, issued on Sep. 14, 2021.
Application 15/664,884 is a continuation of application No. 13/878,954, abandoned, previously published as PCT/US2011/056469, filed on Oct. 14, 2011.
Claims priority of provisional application 61/393,805, filed on Oct. 15, 2010.
Prior Publication US 2022/0177838 A1, Jun. 9, 2022
Int. Cl. C12N 5/078 (2010.01); A61M 1/36 (2006.01); B01D 63/02 (2006.01); A61M 1/16 (2006.01)

CPC C12N 5/0634 (2013.01) [A61M 1/3672 (2013.01); A61M 1/3675 (2013.01); B01D 63/02 (2013.01); A61M 1/1698 (2013.01); A61M 1/3679 (2013.01); A61M 2202/0427 (2013.01); A61M 2202/0439 (2013.01); B01D 2313/44 (2013.01)]

22 Claims

1. A method for processing an activated leukocyte, an activated platelet, or both an activated leukocyte and an activated platelet contained within a body fluid, the method comprising:

(a) providing a cartridge comprising

(i) a rigid housing defining an inner volume (IV), a fluid inlet port and a fluid outlet port, wherein the inner volume is in fluid flow communication with the fluid inlet port and the fluid outlet port; and

(ii) a solid support disposed within the housing and defining a fluid contacting surface with a surface area (SA) capable of sequestering an activated leukocyte and/or an activated platelet if present in a body fluid entering the housing via the fluid inlet port, wherein the cartridge has an SA/IV ratio ranging from greater than 150 cm⁻¹to 800 cm⁻¹; and

(b) introducing a body fluid from a subject into the housing via the fluid inlet port under conditions that permit sequestration of an activated leukocyte and/or an activated platelet on the fluid contacting surface of the solid support; and

(c) treating the leukocyte and/or platelet sequestered in step (b) to inhibit release of a pro-inflammatory substance or to deactivate the leukocyte and/or the platelet.